Business
DNA ImmunoBody Patent Granted in Japan
DNA ImmunoBody Patent Granted in Japan.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3360V Scancell Holdings Plc 12 December 2013 \n \n\n12 December 2013\n \nScancell Holdings Plc\n('Scancell')\n \nDNA ImmunoBody® Patent Granted in Japan\n \n \nScancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in Japan. This key patent follows approval in Australia earlier this year and adds to Scancell's growing body of intellectual property for its ImmunoBody® platform. Scancell's protein ImmunoBody® patent has already been approved in the US, Europe, Japan and Australia.\n \nDr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:\n \n\"This Japanese approval is an important addition as we continue to build a comprehensive IP portfolio for our ImmunoBody® platforms. With the positive results from our SCIB1 study announced earlier this week and the progress we are making on our Moditope® programme, IP plays an increasingly important role in the value ascribed to Scancell's technology. We look forward to building on the momentum of Scancell's progress in 2014.\"\n \nFor Further Information: \n \n\n\n\n\nDr Richard Goodfellow, Joint CEO\nProfessor Lindy Durrant, Joint CEO \n\n\nScancell Holdings Plc\nScancell Holdings Plc\n\n\n+ 44 (0) 20 7831 3113\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCamilla Hume/Stephen Keys\n\n\nCenkos Securities\n\n\n+ 44 (0) 20 7397 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Simon Conway\n\n\nFTI Consulting\n\n\n+ 44 (0) 20 7831 3113\n\n\n\n\n \n \nAbout Scancell\n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and has just completed Phase 1/2 clinical trials which demonstrated that SCIB1 produced a melanoma-specific immune response and promising survival trend. A further higher dose study of SCIB1 will take place during 2014.\n \nScancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where imm...